Key Event Components

Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
A complete list of all KECs is available in TSV format on the Downloads Page.

Showing 26 to 50 of 1146 KECs

ID	Action	Process	Associated Key Events (KEs)


51	decreased	chemical synaptic transmission (GO:0007268)	669: Reduction, Neuronal synaptic inhibition
128	increased	inflammatory response (GO:0006954)	5 Events 149: Increase, Inflammation 901: Infiltration, Inflammatory cells 1087: Increased, inflammation 1225: Immune system inflammation 2097: Increase, Pro-Inflammatory Mediators
2	increased	hyperplasia (MESH:D006965)	3 Events 142: Hyperplasia, Hyperplasia 415: Hyperplasia, Leydig cell 1192: Increased, Ductal Hyperplasia
3	increased	hepatocellular carcinoma (MESH:D006528)	334: Promotion, Hepatocelluar carcinoma
64	decreased	memory (GO:0007613)	341: Impairment, Learning and memory
145	increased	heme oxidation (GO:0006788)	213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)
87	occurrence	oxidative stress (MP:0003674)	None
142	abnormal	larval development (GO:0002164)	2 Events 339: Altered, Larval development 566: impaired, Larval development
71	increased	Disease Susceptibility (MESH:D004198)	323: Increased, Disease susceptibility
123	increased	oxidative stress (MP:0003674)	3 Events 209: Peptide Oxidation 1279: Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK 1392: Increase, Oxidative Stress
10	increased	loss of dopaminergic neurons (MP:0003244)	890: Degeneration of dopaminergic neurons of the nigrostriatal pathway
57	increased	cell death (GO:0008219)	2 Events 55: Increase, Cell injury/death 768: Increase, Cytotoxicity
85	disrupted	protein domain specific binding (GO:0019904)	158: N/A, Interferences with SH-/selen-proteins
13	decreased	ecdysis-triggering hormone activity (GO:0008255)	988: Decrease, Circulating ecdysis triggering hormone
1	increased	cell proliferation (GO:0008283)	3 Events 57: Proliferation, Cell proliferation in the absence of cytotoxicity 416: Increase proliferation, Leydig cell 1182: Increase, Cell Proliferation (Epithelial Cells)
15	increased	muscle contraction (GO:0006936)	2 Events 993: Decrease, Abdominal muscle contraction 601: Overactivation, muscle contraction
16	increased	mortality (MESH:D009026)	4 Events 351: Increased Mortality 350: Increase, Mortality 1135: Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction 947: Increase, Early Life Stage Mortality
83	decreased	population growth rate (PCO:0000008)	4 Events 442: Decreased, Population trajectory 361: Decline, Population 679: Decline, Population trajectory 1136: Impaired recruitment , Population trajectory
63	decreased	synaptic signaling (GO:0099536)	2 Events 386: Decrease of neuronal network function 618: Decreased, Neuronal network function in adult brain
105	morphological change	abnormal cardiovascular system physiology (MP:0001544)	317: Altered, Cardiovascular development/function
140	increased	Kidney Diseases (MESH:D007674)	252: Increase, Renal pathology due to VTG deposition
21	decreased	excitatory postsynaptic potential (GO:0060079)	1268: Decrease, Excitatory postsynaptic potential
112	decreased	oocyte growth (GO:0001555)	309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
149	increased	hemoglobin binding (GO:0030492)	118: Formation, Formation of hemoglobin adducts
122	decreased	long-term synaptic potentiation (GO:0060291)	166: Decreased, Long-term potentiation (LTP)